Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis does not affect cancer progression-free survival: a RADIOS Registry study - PubMed
3 hours ago
- #glucocorticoids
- #cancer survival
- #checkpoint inhibitor
- Oral glucocorticoid treatment for checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) does not adversely affect cancer progression-free survival (PFS).
- The study used data from the RADIOS Registry, analyzing 269 patients with ICI-IA, with a median glucocorticoid dose of 13 mg daily in the first month.
- In adjusted Cox models, glucocorticoid use and doses above the median were not associated with worse PFS, with hazard ratios showing no significant impact.
- The cohort had a mean age of 64.85 years, 48.3% female, 87% White, 32% with melanoma, and most at stage IV cancer.
- Cancer progression occurred in 24.9% of participants, and only 7.8% received immunomodulatory disease-modifying antirheumatic drugs in the first month.
- The findings support the safe use of low-dose glucocorticoids as first-line treatment for ICI-IA without compromising cancer outcomes.